Abstract
Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Volume: 10 Issue: 3
Author(s): Yolanda Diebold, Laura Contreras-Ruiz, Isabel Arranz-Valsero and Laura Garcia-Posadas
Affiliation:
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Abstract: Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Export Options
About this article
Cite this article as:
Diebold Yolanda, Contreras-Ruiz Laura, Arranz-Valsero Isabel and Garcia-Posadas Laura, Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (3) . https://dx.doi.org/10.2174/1871523011109030203
DOI https://dx.doi.org/10.2174/1871523011109030203 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Current Medicinal Chemistry Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Prospective for Diagnosis and Treatment of Diabetic Retinopathy
Current Pharmaceutical Design Intravitreal Triamcinolone in Diabetic Retinopathy
Current Diabetes Reviews Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Updated Review for the Diabetic Wound Healing Systems
Current Drug Targets New Insights in Congenital Diaphragmatic Hernia
Current Respiratory Medicine Reviews Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Current Pharmaceutical Design Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Intraocular Immune Mechanisms in Uveitis
Current Immunology Reviews (Discontinued) Models for the Study of Angiogenesis
Current Pharmaceutical Design MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease
Current Molecular Medicine Use of Anti-VEGF Drugs in Retinal Vein Occlusions
Current Drug Targets Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued)